Status:
COMPLETED
Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication
Lead Sponsor:
University of Virginia
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Peripheral Arterial Disease
Intermittent Claudication
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
Peripheral artery disease (PAD) is a major complication of atherosclerosis when blockages in the arteries to leg reduce blood flow and one of the resulting problems is termed intermittent claudication...
Detailed Description
Peripheral artery disease (PAD) is a major complication of atherosclerosis that affects \>8 million people in the United States alone. Intermittent claudication (IC), defined as leg pain with walking ...
Eligibility Criteria
Inclusion
- Age \>40 years. Patients less than 40 years of age could well have a form or "thromboangitis obliterans" often called Berger's Disease and the investigators wish to enroll only subjects with atherosclerotic vascular disease.
- Currently taking all standard medications that are part of the "good medical care" for patients with PAD including an anti-platlet agent, an angiotensin-converting enzyme inhibitors or receptor blockers, beta-blockers if indicated for ischemic heart disease, and cholesterol lowering therapy; unless documented contra-indications to these therapies exist. Those patients not on these therapies will be referred back with the suggestion that they be added and they can be re-approached for enrollment at a later date.
- Exercise induced thigh, calf, buttock pain and absence of Rutherford Class IV, V, or VI.3
- A resting ABI of \<0.9 but \>0.4 and the presence of both superficial femoral artery stenosis (70% or greater) disease and below the knee disease with a significant stenosis in at least one of the run-off vessels.
- Absence of critical inflow (iliac or common femoral) disease. The profunda femoral artery is the major source of collateral blood vessels. The investigators initial approach will be to try and enroll as homogenous of a patient population as possible to allow us to focus on the primary endpoint of the study (the change in muscle perfusion to the ischemic limb over time).
- Ability to undergo magnetic resonance imaging and provide informed written consent.
Exclusion
- Serious known concomitant disease with life expectancy of less than one year
- Prior amputation or history of critical limb ischemia
- Creatinine clearance (CrCl) \>45 to permit safe administration of the gadolinium contrast agent.
- Recent myocardial infarction, unstable angina, stroke or transient ischemic attack within 3 months.
- American Heart Association Class III or IV congestive heart failure or known left ventricular ejection fraction less than 40%.
- Known history of anemia
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01890135
Start Date
June 1 2013
End Date
June 1 2016
Last Update
August 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Virginia Health System
Charlottesville, Virginia, United States, 22908